Bard and Tyco break off $3.1 billion merger
This article was originally published in Clinica
Conglomerate Tyco International's plan to split into four separate businesses appears to have scuppered its proposed $3.1 billion merger with Bard. The two companies have mutually abandoned their proposed merger two weeks after Tyco's surprise announcement (see Clinica No 993, p 15).
You may also be interested in...
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
Sawai’s sales increased on the back of a good performance from recently-launched products in the first nine months of its financial year. However, given the competitive environment the Japanese company is continuing to stick to its full-year forecasts.